Anxiety and depression in patients with multiple sclerosis Mental and Behavioural Disorders
Conditions
Interventions
The study comparing a psychological group intervention, based on transdiagnostic therapy principles developed by Barlow et al. (the Unified Protocol), with a control group. Group therapy consists of 1
Sponsors
Islamic Azad University of Hamedan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 08/11/2019: 1. Valid MS diagnosis 2. No suicidal Ideation or threatening behaviors, no history span attempted suicide 3. Valid diagnosis of depression or anxiety disorder 4. Internet availability Previous inclusion criteria: 1. Diagnosis of MS for 3 years or more 2. Fluent in Persian 3. At least 18 years of age 4. Received at least one current diagnostic of a valid depression disorder and an anxiety disorder on Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fourth Edition Axis I Disorders 5. Received at least one self-report score, without the cut-off range, specified for each of screening domains: 5.1 Anxiety screening measures included the Penn State Worry Questionnaire (PSWQ), Anxiety Severity and Impairment Scale (OASIS). HADS-A 5.2 Depression screening measures include Anxiety Severity and Impairment Scale ODSIS HADS-D. 5.3 Emotional screening measures include Difficulties in Emotion Regulation Scale (DERS), the Positive and Negative Affect Schedule (PANAS), the Southampton Mindfulness Questionnaire (SMQ), and Emotion Regulation Questionnaire (ERQ-R). 6. Willing to participate in the research 7. Fill and sign consent 8. Medical agreement for participation.
Exclusion criteria
Exclusion criteria: 1. Initial diagnosis of current or past schizophrenia, psychosis, or organic mental disorder, bipolar disorder, or organic mental disorder 2. Other Chronic physical illnesses (such as insulin-dependent diabetes and chemotherapy for cancer) 3. Pregnancy or lactation 4. Drug abuse history or drug dependence except for nicotine 5. Absenteeism for more than three sessions 6. Receiving psychological interventions during previous year 7. Presence of another comorbid neurological disorder such as Alzheimer's disease, Parkinson's disease or dementia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| At baseline, post-treatment (14-weeks), and three months: 1. Psychological or psychiatric diagnosis assessed using SCID-DSM-IV: The Structured Clinical Interview for DSM-IV (SCID) 2. Tendency, intensity and excessiveness of worry assessed using the Penn State Worry Questionnaire (PSWQ) 3. Anxiety symptoms assessed using the Hospital Anxiety and Depression Scale (HADS) anxiety subscale 4. Depression symptoms assessed using the Hospital Anxiety and Depression Scale (HADS) depression subscale | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 08/11/2019: 1. Mindfulness (mindful observation, non-aversion, non-judgment, and letting go) assessed using the Southampton Mindfulness Questionnaire (SMQ) 2. Emotionality assessed using the Emotional style Questionnaire (2019) ESQ 3. Depression symptoms assessed using the Beck Depression Inventory 4. Emotional dysregulation assessed using the Difficulties in Emotion Regulation Scale (DERS) 5. Tendency, intensity and excessiveness of worry assessed using the Penn State Worry Questionnaire (PSWQ) Previous secondary outcome measures: At baseline, post-treatment (14-weeks), and three months: 1. Psychological or psychiatric diagnosis assessed using SCID-DSM-IV: The Structured Clinical Interview for DSM-IV (SCID) 2. Anxiety-related symptom severity and impairment assessed using the Overall Anxiety Severity and Impairment Scale (OASIS) 3. Tendency, intensity and excessiveness of worry assessed using the Penn State Worry Questionnaire (PSWQ) 5. Emotional regulation assessed using the Emotion Regulation Questionnaire (ERQ-R) 6. Positive and negative affect assessed using the Positive and Negative Affect Schedule (PANAS) 7. Mindfulness (mindful observation, non-aversion, non-judgment, and letting go) assessed using the Southampton Mindfulness Questionnaire (SMQ) 8. Emotional dysregulation assessed using the Difficulties in Emotion Regulation Scale (DERS) 9. Anxiety symptoms assessed using the Hospital Anxiety and Depression Scale (HADS) anxiety subscale 10. Depression symptoms assessed using the Hospital Anxiety and Depression Scale (HADS) depression | — |
Countries
Iran
Outcome results
None listed